Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Correlated Gene Expression and Anatomical Communication Support Synchronized Brain Activity in the Mouse Functional Connectome.

Mills BD, Grayson DS, Shunmugavel A, Miranda-Dominguez O, Feczko E, Earl E, Neve KA, Fair DA.

J Neurosci. 2018 Jun 20;38(25):5774-5787. doi: 10.1523/JNEUROSCI.2910-17.2018. Epub 2018 May 22.

PMID:
29789379
2.

Cocaine-induced adaptation of dopamine D2S, but not D2L autoreceptors.

Robinson BG, Condon AF, Radl D, Borrelli E, Williams JT, Neve KA.

Elife. 2017 Nov 20;6. pii: e31924. doi: 10.7554/eLife.31924.

3.

Desensitized D2 autoreceptors are resistant to trafficking.

Robinson BG, Bunzow JR, Grimm JB, Lavis LD, Dudman JT, Brown J, Neve KA, Williams JT.

Sci Rep. 2017 Jun 29;7(1):4379. doi: 10.1038/s41598-017-04728-z.

4.

Effects of D1 receptor knockout on fear and reward learning.

Abraham AD, Neve KA, Lattal KM.

Neurobiol Learn Mem. 2016 Sep;133:265-273. doi: 10.1016/j.nlm.2016.07.010. Epub 2016 Jul 14.

5.

Genetic Polymorphisms Affect Mouse and Human Trace Amine-Associated Receptor 1 Function.

Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, Belknap JK, Eshleman AJ, Phillips TJ, Janowsky A.

PLoS One. 2016 Mar 31;11(3):e0152581. doi: 10.1371/journal.pone.0152581. eCollection 2016.

6.

Activation of D1/5 Dopamine Receptors: A Common Mechanism for Enhancing Extinction of Fear and Reward-Seeking Behaviors.

Abraham AD, Neve KA, Lattal KM.

Neuropsychopharmacology. 2016 Jul;41(8):2072-81. doi: 10.1038/npp.2016.5. Epub 2016 Jan 14.

7.

Distinct regulation of dopamine D2S and D2L autoreceptor signaling by calcium.

Gantz SC, Robinson BG, Buck DC, Bunzow JR, Neve RL, Williams JT, Neve KA.

Elife. 2015 Aug 26;4. doi: 10.7554/eLife.09358.

8.

Role for Rab10 in Methamphetamine-Induced Behavior.

Vanderwerf SM, Buck DC, Wilmarth PA, Sears LM, David LL, Morton DB, Neve KA.

PLoS One. 2015 Aug 20;10(8):e0136167. doi: 10.1371/journal.pone.0136167. eCollection 2015.

9.

Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPA.

Gantz SC, Levitt ES, Llamosas N, Neve KA, Williams JT.

Cell Rep. 2015 Aug 11;12(6):944-54. doi: 10.1016/j.celrep.2015.07.005. Epub 2015 Jul 30.

10.

Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: comparison with functional GTPĪ³S assays.

Zhen J, Antonio T, Ali S, Neve KA, Dutta AK, Reith ME.

J Neurosci Methods. 2015 Jun 15;248:7-15. doi: 10.1016/j.jneumeth.2015.03.028. Epub 2015 Apr 1.

PMID:
25840364
11.

Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor.

Clayton CC, Donthamsetti P, Lambert NA, Javitch JA, Neve KA.

J Biol Chem. 2014 Nov 28;289(48):33663-75. doi: 10.1074/jbc.M114.605378. Epub 2014 Oct 21.

12.

Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Rangel-Barajas C, Malik M, Taylor M, Neve KA, Mach RH, Luedtke RR.

J Neurochem. 2014 Nov;131(4):418-31. doi: 10.1111/jnc.12825. Epub 2014 Aug 19.

13.

Dopamine and extinction: a convergence of theory with fear and reward circuitry.

Abraham AD, Neve KA, Lattal KM.

Neurobiol Learn Mem. 2014 Feb;108:65-77. doi: 10.1016/j.nlm.2013.11.007. Epub 2013 Nov 20. Review.

14.

Normalizing dopamine D2 receptor-mediated responses in D2 null mutant mice by virus-mediated receptor restoration: comparing D2L and D2S.

Neve KA, Ford CP, Buck DC, Grandy DK, Neve RL, Phillips TJ.

Neuroscience. 2013 Sep 17;248:479-87. doi: 10.1016/j.neuroscience.2013.06.035. Epub 2013 Jun 27.

15.

Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway.

Gantz SC, Ford CP, Neve KA, Williams JT.

J Neurosci. 2011 Aug 31;31(35):12629-37. doi: 10.1523/JNEUROSCI.0684-11.2011.

16.

An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors.

Lan H, Teeter MM, Gurevich VV, Neve KA.

Mol Pharmacol. 2009 Jan;75(1):19-26. doi: 10.1124/mol.108.050542. Epub 2008 Sep 26.

17.

A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding.

Lan H, Liu Y, Bell MI, Gurevich VV, Neve KA.

Mol Pharmacol. 2009 Jan;75(1):113-23. doi: 10.1124/mol.108.050534. Epub 2008 Sep 22. Erratum in: Mol Pharmacol. 2009 Mar;75(3):729.

18.

Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function.

Liu Y, Buck DC, Neve KA.

Mol Pharmacol. 2008 Aug;74(2):371-8. doi: 10.1124/mol.108.044925. Epub 2008 Apr 29.

19.

Overview of neural gene expression.

Neve RL, Neve KA.

Curr Protoc Neurosci. 2001 May;Chapter 4:Unit 4.5. doi: 10.1002/0471142301.ns0405s00. Review.

PMID:
18428488
20.

Evidence that calmodulin binding to the dopamine D2 receptor enhances receptor signaling.

Liu Y, Buck DC, Macey TA, Lan H, Neve KA.

J Recept Signal Transduct Res. 2007;27(1):47-65.

PMID:
17365509
21.

Modulation of D2R-NR2B interactions in response to cocaine.

Liu XY, Chu XP, Mao LM, Wang M, Lan HX, Li MH, Zhang GC, Parelkar NK, Fibuch EE, Haines M, Neve KA, Liu F, Xiong ZG, Wang JQ.

Neuron. 2006 Dec 7;52(5):897-909.

22.

Novel features of G protein-coupled receptor kinase 4.

Neve KA.

Mol Pharmacol. 2006 Mar;69(3):673-6. Epub 2005 Dec 9.

23.

Identification of a Zn2+-binding site on the dopamine D2 receptor.

Liu Y, Teeter MM, DuRand CJ, Neve KA.

Biochem Biophys Res Commun. 2006 Jan 20;339(3):873-9.

PMID:
16332354
24.

Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors.

Lan H, Durand CJ, Teeter MM, Neve KA.

Mol Pharmacol. 2006 Jan;69(1):185-94. Epub 2005 Oct 19.

25.

Use of herpes virus amplicon vectors to study brain disorders.

Neve RL, Neve KA, Nestler EJ, Carlezon WA Jr.

Biotechniques. 2005 Sep;39(3):381-91. Review.

26.

Double feature at the signalplex.

Neve KA.

Mol Pharmacol. 2005 Aug;68(2):275-8. Epub 2005 May 27. Review.

27.

Sensitization of adenylate cyclase by Galpha i/o-coupled receptors.

Watts VJ, Neve KA.

Pharmacol Ther. 2005 Jun;106(3):405-21. Epub 2005 Mar 2. Review.

PMID:
15922020
28.
29.

Dopamine D1 receptor interaction with arrestin3 in neostriatal neurons.

Macey TA, Liu Y, Gurevich VV, Neve KA.

J Neurochem. 2005 Apr;93(1):128-34.

30.

Dopamine receptor signaling.

Neve KA, Seamans JK, Trantham-Davidson H.

J Recept Signal Transduct Res. 2004 Aug;24(3):165-205. Review.

PMID:
15521361
31.

Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor.

Torvinen M, Kozell LB, Neve KA, Agnati LF, Fuxe K.

J Mol Neurosci. 2004;24(2):173-80.

PMID:
15456930
32.

Preferential Interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons.

Macey TA, Gurevich VV, Neve KA.

Mol Pharmacol. 2004 Dec;66(6):1635-42. Epub 2004 Sep 10.

33.

DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3.

McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, Kozlowski MR, Neve KA, Neve RL.

J Neurosci. 2003 Jul 30;23(17):6914-27.

34.

Regulation of dopamine D(1) receptor trafficking by protein kinase A-dependent phosphorylation.

Mason JN, Kozell LB, Neve KA.

Mol Pharmacol. 2002 Apr;61(4):806-16.

36.

Regulation of melatonin 1a receptor signaling and trafficking by asparagine-124.

Nelson CS, Ikeda M, Gompf HS, Robinson ML, Fuchs NK, Yoshioka T, Neve KA, Allen CN.

Mol Endocrinol. 2001 Aug;15(8):1306-17.

PMID:
11463855
37.

Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor.

Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, Teeter MM.

Mol Pharmacol. 2001 Aug;60(2):373-81.

38.

CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.

Wilcox RE, Huang WH, Brusniak MY, Wilcox DM, Pearlman RS, Teeter MM, DuRand CJ, Wiens BL, Neve KA.

J Med Chem. 2000 Aug 10;43(16):3005-19.

PMID:
10956209
39.

Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity.

Schutzer WE, Watts VJ, Chapman J, Cumbay MG, Neve KA, Neve RL, Mader SL.

Clin Exp Pharmacol Physiol. 2000 Jan-Feb;27(1-2):9-13.

PMID:
10696522
40.

Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.

Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A.

J Pharmacol Exp Ther. 1999 May;289(2):877-85.

41.

Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors.

Watts VJ, Vu MN, Wiens BL, Jovanovic V, Van Tol HH, Neve KA.

Psychopharmacology (Berl). 1999 Jan;141(1):83-92.

PMID:
9952069
42.

Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells.

Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA.

J Neurosci. 1998 Nov 1;18(21):8692-9.

43.

CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.

Wilcox RE, Tseng T, Brusniak MY, Ginsburg B, Pearlman RS, Teeter M, DuRand C, Starr S, Neve KA.

J Med Chem. 1998 Oct 22;41(22):4385-99.

PMID:
9784114
45.

[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.

Johnson RA, Eshleman AJ, Meyers T, Neve KA, Janowsky A.

Synapse. 1998 Sep;30(1):97-106.

PMID:
9704886
47.

Modulation of rat rotational behavior by direct gene transfer of constitutively active protein kinase C into nigrostriatal neurons.

Song S, Wang Y, Bak SY, During MJ, Bryan J, Ashe O, Ullrey DB, Trask LE, Grant FD, O'Malley KL, Riedel H, Goldstein DS, Neve KA, LaHoste GJ, Marshall JF, Haycock JW, Neve RL, Geller AI.

J Neurosci. 1998 Jun 1;18(11):4119-32.

48.

Constitutive activity of a chimeric D2/D1 dopamine receptor.

Kozell LB, Neve KA.

Mol Pharmacol. 1997 Dec;52(6):1137-49.

49.

Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters.

Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A, Neve KA.

J Neurochem. 1997 Oct;69(4):1459-66.

50.

Supplemental Content

Support Center